Ottobock Q3 2026 results show the world’s largest prosthetics and orthotics company still growing, but more slowly than a year ago. In its third-quarter statement published on 12 November, Ottobock reported organic core revenue growth of 6.4% for July to September, against 12.7% in the same quarter of 2025. Core revenue reached EUR 433.4 million, up 9.0% on a reported basis.
Ottobock Q3 2026 at a glance
- Nine months: core revenue of EUR 1,251.8 million, with organic growth of 6.6%.
- Profitability: underlying core EBITDA rose 13.5% to EUR 120.1 million in Q3, lifting the margin to 27.7%.
- Guidance: confirmed at 6% to 8% organic core growth for 2026, with an underlying core EBITDA margin above 27%.
Where Ottobock grew
EMEA, the segment that covers Europe, the Middle East and Africa, grew 8.0% organically in the quarter. Ottobock attributed this to double-digit growth in its products and components business and continued contributions from Russia and Ukraine, partly offset by softer trading in Western Europe. Russia accounted for more than 11% of reported group revenue over the nine months.
Asia-Pacific was the standout at 17.9%, helped by a tender-related catch-up and strong momentum in Australia and Thailand. The Americas declined 1.8% against strong prior-year comparisons in the United States and weaker demand in Canada and Brazil.
Components lead, patient care slows
Products and components grew 9.9% in Q3, driven by high-tech prosthetics and neuro-orthotics such as the myoelectric michelangelo hand and the C-Brace Interim. Ottobock’s own patient care clinics grew just 1.7%. The company said patient care stayed positive in every region but below its ambition, partly because reimbursement approvals are taking longer in several European markets.
Chief executive Oliver Jakobi described a more challenging market environment and said the company expects the reimbursement headwinds to persist into the fourth quarter. He added that the structural drivers of demand remain firmly intact.
IMEA CPO Perspective
Ottobock does not break out the Middle East or Africa, so the regional reading below is IMEA CPO’s analysis rather than a company statement. Even so, the results carry three signals for CPOs and clinic owners across the IMEA region:
- Suppliers will look harder at growth markets. With Western European patient care slowed by reimbursement, the GCC, Africa and South Asia become more attractive for component sales, training and distribution investment.
- Reimbursement shapes revenue everywhere. If approval delays can hold back a business of Ottobock’s size, clinics in the region should treat documentation, pre-approvals and insurer relationships as core business tasks.
- Tenders still move the numbers. The APAC catch-up shows how public procurement timing can swing a quarter, a pattern familiar to anyone bidding into ministry and hospital tenders in the Gulf and Africa.
Ottobock will publish its 2027 guidance with its full-year results in March 2027. IMEA CPO covered the company’s first-half results in August and will continue to track its activity in the region, from Ottobock Kenya to its investment in Blue Arbor.
Suggested Hyperlinks
- Ottobock: Q3 and nine-month 2026 results (12 November 2026)
- Ottobock investor relations: results and reports
- IMEA CPO: Ottobock H1 2026 results
- IMEA CPO: Russia’s prosthetic imports from Germany